FI950947A0 - Oraalisesti annettavat farmaseuttiset formulaatiot - Google Patents

Oraalisesti annettavat farmaseuttiset formulaatiot

Info

Publication number: FI950947A0
Authority: FI; Finland
Prior art keywords: pharmaceutical formulations; oral administration; raloxifene; ethers; pharmaceutically
Prior art date: 1994-03-02

Application number

FI950947A

Other languages

English (en)

Swedish (sv)

Other versions

FI117042B (fi

FI950947A (fi

Inventor

Lowell Lee Gibson

Kerry John Hartauer

Julian Larry Stowers

Stephanie Ann Sweetana

Arvind Lavji Thakkar

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-02

Filing date

1995-03-01

Publication date

1995-03-01

1995-03-01 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1995-03-01 Publication of FI950947A0 publication Critical patent/FI950947A0/fi

1995-09-03 Publication of FI950947A publication Critical patent/FI950947A/fi

2006-05-31 Application granted granted Critical

2006-05-31 Publication of FI117042B publication Critical patent/FI117042B/fi

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Obesity (AREA)
Hematology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

FI950947A 1994-03-02 1995-03-01 Oraalisesti annettavat farmaseuttiset formulaatiot FI117042B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US20491594A	1994-03-02	1994-03-02
US20491594		1994-03-02
SG1997000220A SG65636A1 (en)	1994-03-02	1997-01-30	Orally administrable pharmaceutical formulations
SG9700220		1997-01-30

Publications (3)

Publication Number	Publication Date
FI950947A0 true FI950947A0 (fi)	1995-03-01
FI950947A FI950947A (fi)	1995-09-03
FI117042B FI117042B (fi)	2006-05-31

Family

ID=26665140

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI950947A FI117042B (fi)	1994-03-02	1995-03-01	Oraalisesti annettavat farmaseuttiset formulaatiot

Country Status (22)

Country	Link
EP (1)	EP0670162B1 (fi)
JP (1)	JP3574210B2 (fi)
CN (1)	CN1098684C (fi)
AT (1)	ATE211910T1 (fi)
AU (1)	AU684882B2 (fi)
BR (1)	BR9500758A (fi)
CA (1)	CA2143263C (fi)
CZ (1)	CZ286119B6 (fi)
DE (1)	DE69524981T2 (fi)
DK (1)	DK0670162T3 (fi)
ES (1)	ES2166799T3 (fi)
FI (1)	FI117042B (fi)
HU (1)	HU225418B1 (fi)
IL (1)	IL112746A (fi)
NO (1)	NO314286B1 (fi)
NZ (1)	NZ270588A (fi)
PL (1)	PL178858B1 (fi)
PT (1)	PT670162E (fi)
RU (1)	RU2118540C1 (fi)
SG (1)	SG65636A1 (fi)
SI (1)	SI0670162T1 (fi)
ZA (1)	ZA951497B (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en)	1993-05-13	2001-06-26	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
WO1996040098A2 (en)	1995-06-07	1996-12-19	Neorx Corporation	Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
IL140742A (en) *	1996-03-26	2012-02-29	Lilly Co Eli	Reloxifen and pharmaceuticals containing it
US6458811B1 (en)	1996-03-26	2002-10-01	Eli Lilly And Company	Benzothiophenes formulations containing same and methods
ZA979723B (en)	1996-10-30	1999-07-29	Lilly Co Eli	Methods of preventing breast cancer.
CA2219070C (en) *	1996-10-30	2007-12-18	Eli Lilly And Company	Methods of preventing breast cancer
WO1998046588A2 (en)	1997-04-11	1998-10-22	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6413533B1 (en) *	1998-05-07	2002-07-02	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
CA2394636A1 (en) *	1999-12-13	2001-06-14	Chugai Seiyaku Kabushiki Kaisha	Compound having hydroxycarbonyl-halogenoalkyl side chains
JP4798924B2 (ja) *	1999-12-13	2011-10-19	中外製薬株式会社	ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物
AR029538A1 (es) *	2000-07-06	2003-07-02	Wyeth Corp	Composiciones farmaceuticas de agentes estrogenicos
EP1381384B1 (en) *	2001-04-24	2011-05-25	Merck Patent GmbH	COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
EP1832583A1 (en)	2002-09-30	2007-09-12	A/S GEA Farmaceutisk Fabrik	Novel raloxifene sulphuric acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these
US20050008704A1 (en) *	2003-07-11	2005-01-13	Ray Anup Kumar	Pharmaceutical composition for solubility enhancement of hydrophobic drugs
AU2007264418B2 (en)	2006-06-30	2012-05-03	Iceutica Pty Ltd	Methods for the preparation of biologically active compounds in nanoparticulate form
EP2197423B1 (en) *	2007-10-16	2014-12-03	Pharmathen S.A.	Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
EP2242483B1 (en) *	2007-12-21	2013-02-20	Synthon B.V.	Raloxifene composition
CN103932988A (zh)	2009-04-24	2014-07-23	伊休蒂卡有限公司	吲哚美辛的新剂型
WO2011000581A2 (en) *	2009-07-02	2011-01-06	Synthon B.V.	Raloxifene composition
WO2011099942A1 (en)	2010-02-09	2011-08-18	Silverstone Pharma	New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN103006570B (zh) *	2012-10-08	2013-12-25	孙维会	一种阿佐昔芬速释微丸及其制备方法
WO2014082651A1 (en) *	2012-11-30	2014-06-05	Pharmathen S.A.	Novel method for improving the bioavailability of low aqueous solubility drugs
CN103830197A (zh) *	2014-03-14	2014-06-04	崔书豪	一种盐酸雷洛昔芬分散片及其制备方法
US9526734B2 (en)	2014-06-09	2016-12-27	Iceutica Pty Ltd.	Formulation of meloxicam
KR102612983B1 (ko) *	2016-09-30	2023-12-13	한미약품 주식회사	용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) *	1992-07-28	1999-08-11	Lilly Co Eli	The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

1995
- 1995-02-23 BR BR9500758A patent/BR9500758A/pt not_active Application Discontinuation
- 1995-02-23 IL IL11274695A patent/IL112746A/xx not_active IP Right Cessation
- 1995-02-23 ZA ZA951497A patent/ZA951497B/xx unknown
- 1995-02-23 CA CA002143263A patent/CA2143263C/en not_active Expired - Lifetime
- 1995-02-24 RU RU95102924A patent/RU2118540C1/ru not_active IP Right Cessation
- 1995-02-24 CZ CZ1995499A patent/CZ286119B6/cs not_active IP Right Cessation
- 1995-02-27 CN CN95100822A patent/CN1098684C/zh not_active Expired - Lifetime
- 1995-02-28 NZ NZ270588A patent/NZ270588A/en unknown
- 1995-02-28 ES ES95301291T patent/ES2166799T3/es not_active Expired - Lifetime
- 1995-02-28 DK DK95301291T patent/DK0670162T3/da active
- 1995-02-28 AT AT95301291T patent/ATE211910T1/de active
- 1995-02-28 PT PT95301291T patent/PT670162E/pt unknown
- 1995-02-28 DE DE69524981T patent/DE69524981T2/de not_active Expired - Lifetime
- 1995-02-28 EP EP95301291A patent/EP0670162B1/en not_active Expired - Lifetime
- 1995-02-28 SI SI9530581T patent/SI0670162T1/xx unknown
- 1995-03-01 FI FI950947A patent/FI117042B/fi not_active IP Right Cessation
- 1995-03-01 HU HU9500635A patent/HU225418B1/hu not_active IP Right Cessation
- 1995-03-01 JP JP4177395A patent/JP3574210B2/ja not_active Expired - Lifetime
- 1995-03-01 PL PL95307491A patent/PL178858B1/pl not_active IP Right Cessation
- 1995-03-01 NO NO19950799A patent/NO314286B1/no not_active IP Right Cessation
- 1995-03-01 AU AU13548/95A patent/AU684882B2/en not_active Expired
1997
- 1997-01-30 SG SG1997000220A patent/SG65636A1/en unknown

Also Published As

Publication number	Publication date
PL307491A1 (en)	1995-09-04
CA2143263A1 (en)	1995-09-03
DK0670162T3 (da)	2002-03-11
SG65636A1 (en)	1999-06-22
ES2166799T3 (es)	2002-05-01
RU2118540C1 (ru)	1998-09-10
NO314286B1 (no)	2003-03-03
DE69524981D1 (de)	2002-02-21
PL178858B1 (pl)	2000-06-30
CZ286119B6 (cs)	2000-01-12
FI117042B (fi)	2006-05-31
SI0670162T1 (en)	2002-06-30
ATE211910T1 (de)	2002-02-15
BR9500758A (pt)	1995-10-24
HU9500635D0 (en)	1995-04-28
AU684882B2 (en)	1998-01-08
NO950799L (no)	1995-09-04
IL112746A0 (en)	1995-05-26
ZA951497B (en)	1996-08-23
DE69524981T2 (de)	2002-08-29
NO950799D0 (no)	1995-03-01
PT670162E (pt)	2002-06-28
EP0670162B1 (en)	2002-01-16
HU225418B1 (en)	2006-11-28
IL112746A (en)	1999-12-31
AU1354895A (en)	1995-09-07
JPH07277973A (ja)	1995-10-24
FI950947A (fi)	1995-09-03
EP0670162A1 (en)	1995-09-06
CA2143263C (en)	2002-01-08
CN1098684C (zh)	2003-01-15
NZ270588A (en)	1996-01-26
JP3574210B2 (ja)	2004-10-06
HUT72661A (en)	1996-05-28
CN1112420A (zh)	1995-11-29
CZ49995A3 (en)	1995-10-18

Publication	Publication Date	Title
FI950947A0 (fi)	1995-03-01	Oraalisesti annettavat farmaseuttiset formulaatiot
HRP20000494B1 (en)	2009-02-28	Pharmaceutically active morpholinol
ITBO910024A1 (it)	1992-07-30	Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
ATE238036T1 (de)	2003-05-15	Autoklavierbare pharmazeutische zusammensetzungen mit komplexbildner
DZ1876A1 (fr)	2002-02-17	Médicaments pour administration orale.
IT8619675A0 (it)	1986-03-07	Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale.
ITRM910696A0 (it)	1991-09-18	Composizioni farmaceutiche per l'applicazione per via nasale.
AU6945491A (en)	1991-07-25	Pimobendan compositions
HK1045113A1 (zh)	2002-11-15	給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
IT1231012B (it)	1991-11-08	Composizione farmaceutica per uso orale contenente nac.
MY101566A (en)	1991-12-17	Pharmaceutical compositions.
EP0670166A3 (en)	1996-06-12	Pharmaceutical compositions for oral administration.
CS240991A3 (en)	1992-03-18	Solid forms for oral administration, said forms containing iphosphamide as active component
ITRM920535A0 (it)	1992-07-14	Composizione farmaceutica per la somministrazione attraverso le mucose.
IT1243358B (it)	1994-06-10	Composizioni farmaceutiche per la somministrazione orale di irudina
IT8621395A0 (it)	1986-08-01	Composizione farmaceutica orale a base di ubichinoni.
MY117590A (en)	2004-07-31	Orally administerable pharmaceutical formulations
FI903885A0 (fi)	1990-08-06	Ny oral farmaceutisk doseringsform som foerbaettrar biotillgaengligheten.
DE69208913D1 (de)	1996-04-18	2-Oxindol-1-carboxamidderivat enthaltendes Arzneimittel zur rektalen Verabreichung
IT8819541A0 (it)	1988-02-25	Composizione farmaceutica per somministrazione nasale.
IE900393L (en)	1990-08-06	Pharmaceutical compositions for oral administration
ITPD920141A1 (it)	1994-01-30	Formulazioni farmaceutiche per la somministraziane orale di calcitonina
ATA172297A (de)	2001-10-15	Pharmazeutische orale zusammensetzung enthaltend fk506

Legal Events

Date	Code	Title	Description
2006-05-31	FG	Patent granted	Ref document number: 117042 Country of ref document: FI
2014-11-03	MM	Patent lapsed

Date

Code

Title

Description

2006-05-31

Patent granted

Ref document number: 117042

Country of ref document: FI

2014-11-03

Patent lapsed